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Screening for Cognitive Impairment in Primary Brain Tumor Patients:
A Preliminary Investigation with the MMSE and RBANS

Farah Aslanzadeh, MS1 Sarah Braun, MS1,2 Julia Brechbiel, MS1 Kelcie Willis, MS1 Kyra Parker 4 Autumn Lanoye, PhD3 & Ashlee Loughan, PhD1,3
Virginia Commonwealth University, Department of Neurology, Division of Neuro-Oncology, Richmond VA;1 Medical University of South Carolina, Charleston SC;2
Massey Cancer Center, Richmond VA;3 Virginia Polytechnic State Institute and State University, Blacksburg VA4

BACKGROUND

METHODS cont.

• The Mini-Mental State Examination (MMSE) is regularly used to
screen for cognitive impairment and is reported as the second
most used cognitive screener by physicians.1-2
• However, the MMSE is less sensitive to mild neurocognitive
disorders (mNCD) such as that commonly seen among primary
brain tumor (PBT) patients.3
• In PBT patients, the MMSE has been shown to have dismal
sensitivity to cognitive impairment and poor sensitivity to
change.4-5
• Comparison between the MMSE, MoCA, and a comprehensive
neuropsychological battery revealed extremely poor sensitivity
of the MMSE to mNCD and that no cut score for either screener
was adequate for optimal sensitivity and specificity.6
• More comprehensive screening tools, such as the Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS), may be more suitable for use with PBT patients.7

Data Analytic Plan:
• Frequencies determined proportion of impairment for each
screener. Chi-square analyses indicated difference between
proportions.
• Binary logistical regression and ROC analysis assessed
specificity and sensitivity for the MMSE-2 to detect the level of
impairment identified on a “positive screen” of the RBANS.

AIMS
• Compare the proportion of impairment indicated on both the
MMSE-2 and RBANS in PBT patients and conduct preliminary
analysis of the sensitivity and specificity of the MMSE-2 to the
level of cognitive impairment identified on the RBANS.
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RESULTS
• Significantly fewer patients were identified as impaired on the
MMSE-2 (33%; n = 27) than on the RBANS (52%; n=64 ; χ2=17.57,
p=<.01).
Proportion of Impairment by Screener

METHODS
• Procedures & Participants:
• Retrospective study of 81 PBT patients at a Mid-Atlantic
urban academic medical cancer center.
• Inclusion criteria were as follows: (1) confirmed PBT
diagnosis via histopathology; (2) a minimum of 2 weeks
post-surgical resection or biopsy (if applicable); and (3)
English speaking.
• Mage = 49 yrs., 50.6% Men, 96.3% White
• Data obtained from neuropsychological evaluations and
medical record
• Neuropsychological Measures:
• Test of Premorbid Functioning (TOPF)8
• MMSE-21
• Impairment defined as a score <27
• RBANS7
• Impaired performance defined as at least one index
score ≥1 standard deviation below TOPF10

SENSITIVITY & SPECIFICITY
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• When evaluating the sensitivity of the MMSE-2 to a “positive screen”
on the RBANS, defined as one or more impaired indices, sensitivity
was 38.2% (95% CI = 26.71% to 50.82%) and specificity was 92.3%
(CI = 63.97% to 99.81%).
• The positive predictive value of the MMSE-2 was 96.3% (CI =
79.43% to 99.43%). The negative predictive value was 22.2% (CI =
18.29% to 26.72%). Accuracy of the MMSE-2 was 46.91% (CI =
35.73% to 58.33%).
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DISCUSSION
• Medical practitioners should consider alternative screeners and
rely less heavily on the MMSE-2 within neuro-oncology clinics
given the relative rates of indicated impairment and preliminary
evidence regarding the MMSE-2’s sensitivity to the level of
cognitive impairment detected on the RBANS.
• While it appears that the MMSE-2 accurately categorizes those
with true cognitive impairment as impaired (i.e., true positives),
results suggest that an individual scoring >27 on the MMSE-2
is still rather likely to be categorized as impaired on other, more
comprehensive screeners (i.e., false negatives).
• More comprehensive screeners such as the RBANS may have
greater clinical utility in screening for cognitive impairment
among PBT patients, particularly if the objective of screening is
to minimize false negatives and increase access to additional
supports.
• Future studies should assess the relative utility of screeners
among PBT patients by using a comprehensive
neuropsychological test battery to assess sensitivity and
specificity to a diagnosis of mNCD.
• Additionally, feasibility and acceptability research is needed to
assess if use of the RBANS in neuro-oncology clinics for
screening is a possible when a neuropsychologist is not part of
the integrated care team.
• In sum, if clinicians rely solely on the MMSE-2, as is common
practice in many medical centers, patients who could benefit
from additional services may go undetected.

